New drug combo tested to halt uterine Pre-Cancer before it turns deadly
NCT ID NCT04576104
Summary
This study is testing if adding a common diabetes drug, metformin, to the standard hormone therapy (megestrol acetate) works better to control a uterine pre-cancer condition. It involves 51 women who are already scheduled for a hysterectomy or IUD placement. The goal is to see if the two-drug combination reduces abnormal cell growth more effectively than the standard single drug alone before their planned procedure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Northwestern Medicine Central DuPage Hospital
Winfield, Illinois, 60190, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University of Colorado
Denver, Colorado, 80217-3364, United States
-
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.